IP Library › Granted Patent US 12709761
Granted Patent B2
US 12709761 · App. 18/060,776 · Granted Aug 18, 2026

Engineered adenovirus vectors and uses thereof

Inventor: Richard Lowenthal (San Diego, CA)
C12N15/86C12N2710/10022C12N2710/10043C12N2710/10051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12709761
App. No.
18/060,776
Granted
Aug 18, 2026
Kind
B2
Abstract

Disclosed herein relates to a replication competent recombinant adenovirus comprising restriction enzyme sites in an E3 region to insert a gene of interest. Also disclosed herein is a method for generating the replication competent recombinant adenovirus and a pharmaceutical composition comprising the adenovirus for use in treating a disease or a condition.

Claims (19)

1 . A replication competent recombinant oncolytic adenovirus comprising restriction sites comprising an I-CeuI restriction site, a PI-SceI restriction site, or a combination thereof in an E3 region, wherein the E3 region does not comprise a deletion as compared to a wild type adenovirus of the same serotype.

2 . The replication competent recombinant oncolytic adenovirus of claim 1 , wherein the restriction sites of E3 region comprise the I-CeuI restriction site and the PI-SceI restriction site.

3 . The replication competent recombinant oncolytic adenovirus of claim 2 , further comprising a heterologous nucleotide sequence located between the I-CeuI restriction site and the PI-SceI restriction site.

4 . The replication competent recombinant oncolytic adenovirus of claim 3 , wherein the heterologous nucleotide sequence is cloned from a shuttle vector.

5 . The replication competent recombinant oncolytic adenovirus of claim 4 , wherein the shuttle vector is a pShuttle or pShuttleX vector.

6 . The replication competent recombinant oncolytic adenovirus of claim 3 , wherein the heterologous nucleotide sequence comprises a gene.

7 . The replication competent recombinant oncolytic adenovirus of claim 6 , wherein the gene encodes a cytokine, a chemokine, a checkpoint inhibitor, or an interleukin.

8 . The replication competent recombinant oncolytic adenovirus of claim 6 , wherein the heterologous nucleotide sequence comprises a Reduced Expression in Immortalized Cells (REIC) gene sequence or an Interleukin-2 (IL-2) gene sequence.

9 . The replication competent recombinant oncolytic adenovirus of claim 5 , further comprising an exogenous promoter operably linked to the E3 region, the E1 region, or the heterologous nucleotide sequence.

10 . The replication competent recombinant oncolytic adenovirus of claim 9 , wherein the exogenous promoter comprises (i) a tissue specific promoter or (ii) a CAG promoter system.

11 . The replication competent recombinant oncolytic adenovirus of claim 1 , wherein the restriction sites of E3 region consist of the I-CeuI restriction site and the PI-SceI restriction site.

12 . The replication competent recombinant oncolytic adenovirus of claim 1 , wherein further comprising an E1 region, wherein (i) the E1 region comprises a same sequence as compared to a wild type adenovirus of the same serotype; (ii) the E1 region comprises a partial deletion compared to a wild type adenovirus of the same serotype; (iii) the E1 region of the adenovirus does not contain an insertion of a heterologous nucleotide sequence; and/or (iv) the E1 region comprises an E1B-55k deletion.

13 . The replication competent recombinant oncolytic adenovirus of claim 1 , wherein the adenovirus further comprises a modification in an E1a, E1b, E2, or E4 gene.

14 . The replication competent recombinant oncolytic adenovirus of claim 1 , further comprising a polynucleotide sequence encoding a modified adenoviral fiber protein.

15 . The replication competent recombinant oncolytic adenovirus of claim 14 , wherein the modified adenoviral fiber protein is an Ad35 fiber tail protein.

16 . The replication competent recombinant oncolytic adenovirus of claim 1 , wherein the adenovirus is selected from the group consisting of adenovirus type 2, adenovirus type 4, adenovirus type 5, and adenovirus type 7.

17 . The replication competent recombinant oncolytic adenovirus of claim 1 , wherein the adenovirus preferentially replicates in a tumor cell as compared to a non-tumor cell.

18 . The replication competent recombinant oncolytic adenovirus of claim 17 , wherein the tumor cell comprises a mutation in a p53 gene or a reduced level of the p53 gene expression as compared to a non-tumor cell.

19 . A composition, comprising the replication competent recombinant oncolytic adenovirus of claim 1 .